Celgene Corporation
Data from Studies of Amrubicin in Small-Cell Lung Cancer Presented at the 2008 American Society of Clinical Oncology Meeting Demonstrate Single Agent Anti-Tumor Activity in Western Patient Population
Published in Blood Weekly, June 19th, 2008
Celgene Corporation (Nasdaq:CELG) announced physicians from leading medical centers presented data from two Phase II clinical studies of amrubicin in patients with extensive-disease small-cell lung cancer (SCLC) either sensitive to platinum-based first-line therapy or refractory to platinum-based first-line therapy. Results of the studies demonstrated improved overall response rates that compare favorably with topotecan, as well as no evidence of anthracycline-induced cardiotoxicity with cumulative dosing up to 1,000 mg of amrubicin.
In the first study, a randomized, multi-center U.S. study involving 48 centers, patients with SCLC and sensitive to previous first-line...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2008-06-19)
More Articles from Blood Weekly
- McGill University Health Centre
Hip and knee replacement patients not receiving treatment to reduce blood clot risk - Research
Policy environments may shape international progress of human embryonic stem cell research - Alpha-thalassemia
New alpha-thalassemia findings from Mahidol University published - Angiotensins
Study data from M.A. Richardson et al provide new insights into angiotensins - Breast Cancer
Researchers from University of Indianapolis report recent findings in breast cancer - Cell Therapeutics, Inc.
Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan Zevalin Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
